DNAtrix Merges With VectorLogics

Houston-based biotechnology firm DNAtrix said today that it has merged with VectorLogics, a firm developing products for the treatment of ovarian cancer. Financial details of the merger were not announced by the companies. DNAtrix is developing adenovirus-based oncolytic virus products for treating brain cancer. The firm's lead candidate is in clinical testing at the University of Texas M.D. Anderson Cancer Center.